Hjem › Ulcerøs colitis › New York
Ulcerøs colitis kliniske forsøg i New York
30 studier for Ulcerøs colitis søger deltagere på steder i New York.
Byer i New York
Officiel studietekst (engelsk)
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
- New York Gastroenterology Associates ( Site 0253), New York
RekruttererFase 3
Alle aldre · Alle køn · Opdateret 2. okt. 2026 · NCT06651281Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- New York Gastroenterology Associates - Upper East Side /ID# 281767, New York
RekruttererFase 2
Alder 18 til 75 · Alle køn · Opdateret 2. okt. 2026 · NCT07697456A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Westchester Putnam Gastroenterology PC, Carmel
- Five Towns Gastroenterology, Cedarhurst
- IMIDeology, Elmhurst
- og 5 flere
RekruttererFase 4
Alder 18 til 80 · Alle køn · Opdateret 30. sep. 2026 · NCT06581328A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
- Ellipsis Research Group, Brooklyn
- Smart Medical Research - Jackson Heights, Jackson Heights
- Pioneer Clinical Research NY, New York
- og 1 flere
RekruttererFase 2
Alder 18 til 75 · Alle køn · Opdateret 30. sep. 2026 · NCT06598943Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
- Xencor Investigative Site, Albany
- Xencor Investigative Site, Rochester
RekruttererFase 1/2Frivillige med god helbredstilstand velkomne
Alder 18 til 75 · Alle køn · Opdateret 29. sep. 2026 · NCT06619990A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
- Site 037, New York
RekruttererFase 2
Alder 18 til 75 · Alle køn · Opdateret 29. sep. 2026 · NCT07012395A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis
- Site US-002, Albany
- Site US-016, Rochester
RekruttererFase 2
Alder 18 til 75 · Alle køn · Opdateret 29. sep. 2026 · NCT07845487A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
- Intercity Gastroenterology, Fresh Meadows
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT06979336A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
- Westchester Putnam Gastroenterology, Carmel
- Inflammatory Bowel Disease Center at NYU Langone, New York
- Icahn School of Medicine at Mount Sinai, New York
- og 3 flere
RekruttererFase 3
Alder 12 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT07196748A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
- Columbia University Medical Center, New York
RekruttererFase 2/3
Alder 2 til 17 · Alle køn · Opdateret 24. sep. 2026 · NCT05076175Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Icahn School of Medicine at Mount Sinai, New York
- New York Gastroenterology Associates, New York
- Care Access - Yonkers, Yonkers
RekruttererFase 3
Alder 18 til 70 · Alle køn · Opdateret 24. sep. 2026 · NCT06937086Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- NYU Langone Hospital - Long Island, Mineola
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- og 1 flere
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 23. sep. 2026 · NCT03816345LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
- Digestive Disease Medicine of Central New York, Utica
RekruttererFase 2
Alder 18 til 80 · Alle køn · Opdateret 22. sep. 2026 · NCT07186101A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
- Icahn School of Medicine at Mount Sinai, New York
RekruttererFase 3
Alder 2 til 19 · Alle køn · Opdateret 22. sep. 2026 · NCT04844606LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
- Stony Brook University, Stony Brook
RekruttererFase 2
Alder 18 til 80 · Alle køn · Opdateret 22. sep. 2026 · NCT07415044A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
- NYU Langone Health, New York
- Weill Cornell Medical College- New York Presbyterian Hospital, New York
RekruttererFase 4
Alder 18 til 65 · Alle køn · Opdateret 21. sep. 2026 · NCT06095128A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
- MedTraits NY - Site Number: 8400045, Maspeth
- Weill Cornell Medicine - NewYork-Presbyterian Hospital - Site Number: 8400040, New York
- New York Gastroenterology Associates - Site Number: 8400009, New York
RekruttererFase 3
Alder 16 til 80 · Alle køn · Opdateret 15. sep. 2026 · NCT07185009A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
- New York Gastroenterology Associates, New York
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 28. aug. 2026 · NCT07577856A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis
- Fink Children's Ambulatory Care Center, New York
- Kimmel Pavilion - NYU Langone, New York
- NYU Grossman School of Medicine, New York
- og 4 flere
RekruttererFase 2
Alder 2 til 11 · Alle køn · Opdateret 24. aug. 2026 · NCT07470879A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis
- Columbia University Medical Center, New York
RekruttererFase 2
Alder 18 til 80 · Alle køn · Opdateret 21. aug. 2026 · NCT06636656An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
- MedTraits NY - Site Number: 8400045, Maspeth
- Manhattan Clinical Research, LLC - Site Number: 8400069, New York
- NYU Langone Health - Site Number: 8400091, New York
- og 4 flere
RekruttererFase 3
Alder 16 til 80 · Alle køn · Opdateret 20. aug. 2026 · NCT07184996Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
- Saratoga Schenectady Gastroenterology Associates, Burnt Hills
- NYU Langone Health, New York
- Cornell University, New York
Rekrutterer
Alder 18 og opefter · Alle køn · Opdateret 7. aug. 2026 · NCT05230173BOOM-IBD2 Pivotal Clinical Trial
- Northwell Health North Shore University Hospital, Manhasset
- Columbia University Irving Medical Center/New York Presbyterian Hospital, New York
Rekrutterer
Alder 18 til 85 · Alle køn · Opdateret 6. aug. 2026 · NCT06571669Zymfentra (Infliximab-dyyb) REal World Cohort STudy
- New York University, New York
RekruttererObservationsstudie
Alder 18 og opefter · Alle køn · Opdateret 5. aug. 2026 · NCT07237516An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis
- NYU Langone Health, New York
- Lenox Hill Hospital, Northwell Health, New York
RekruttererObservationsstudie
Alder 18 til 64 · Alle køn · Opdateret 9. jul. 2026 · NCT06398626A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- New York Presbyterian Hospital, New York
RekruttererFase 3
Alder 2 til 17 · Alle køn · Opdateret 22. jun. 2026 · NCT06405087A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, New York
- Mirador Therapeutics Selected Site, Rochester
RekruttererFase 2
Alder 18 til 80 · Alle køn · Opdateret 12. mar. 2026 · NCT07113522Hyperbaric Oxygen Therapy for Ulcerative Colitis (HBOT-UC)
- State University of New York Upstate Medical University, Syracuse
Rekrutterer
Alder 18 til 85 · Alle køn · Opdateret 8. jan. 2026 · NCT05987852Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis
- Bausch Health Site 006, The Bronx
RekruttererFase 4
Alder 5 til 17 · Alle køn · Opdateret 16. sep. 2025 · NCT04314375Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention
- New York University, New York
RekruttererObservationsstudie
Alder 18 og opefter · Alle køn · Opdateret 8. maj 2025 · NCT06750731Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.